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REGULAR ARTICLE
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Key Points

• In randomized trials,
treatment effect estimates based on the
hazard ratios were unaffected by various EFS
definitions.
• In single-arm trials, incorrect conclusions
about efficacy could be
made if the EFS definition is not consistent
with the historical
control.

Event-free survival (EFS) is controversial as an end point for speeding approvals in newly
diagnosed acute myeloid leukemia (AML). We aimed to examine the robustness of EFS,
speciﬁcally timing of complete remission (CR) in deﬁning induction failure and impact of
hematopoietic cell transplantation (HCT). The study included 1884 untreated AML patients
enrolled across 5 trials conducted through Alliance for Clinical Trials in Oncology using
anthracycline and cytarabine induction chemotherapy. EFS was deﬁned as time from
randomization/registration to induction failure, relapse, or death. Three deﬁnitions of
induction failure were evaluated: failure to achieve CR by 60 days after randomization/
registration, failure to achieve CR by the end of all protocol-deﬁned induction courses, and
failure to achieve CR by the end of all protocol-deﬁned treatment. We considered either
censoring or no censoring at time of non–protocol-mandated HCT. Although relapse and
death are ﬁrm end points, the determination of induction failure was not consistent across
studies. There was minimal impact of censoring at HCT on EFS estimates; however, median
EFS estimates differed considerably based on the timing of CR in deﬁning induction failure,
with the magnitude of difference being large enough in most cases to lead to incorrect
conclusions about eﬃcacy in a single-arm trial, if the trial deﬁnition was not consistent with
the deﬁnition used for the historical control. Timing of CR should be carefully examined in
the historical control data used to guide the design of single-arm trials using EFS as the
primary end point. Trials were registered at www.clinicaltrials.gov as #NCT00085124,
#NCT00416598, # NCT00651261, #NCT01238211, and #NCT01253070.

Introduction
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and is among the most
lethal. In the United States, the annual incidence of AML is 19 000 cases, and the annual incidence of
AML-associated deaths is 10 000.1 Although there has been significant research effort aimed at
improving outcomes in AML, standard therapy for most subtypes of newly diagnosed AML remains
suboptimal.1,2 Especially among patients age .60 years, outcomes are poor, with a 5-year overall
survival (OS) of 10% to 20%; outcomes are even worse among older patients who are unfit for
intensive chemotherapy, with a median OS of only 5 to 10 months.1,3,4
In parallel with research on new therapies, emphasis has been placed on new end points other than
OS that may facilitate drug development and shorten the time to approval for use in AML.2,5 OS in
comparative oncology clinical trials remains the gold-standard end point to assess efficacy of drugs for
Submitted 14 September 2018; accepted 15 March 2019. DOI 10.1182/
bloodadvances.2018026112.

© 2019 by The American Society of Hematology

The full-text version of this article contains a data supplement.

1714

11 JUNE 2019 x VOLUME 3, NUMBER 11

From www.bloodadvances.org by guest on July 3, 2019. For personal use only.

approval by the US Food and Drug Administration. However, use
of OS as an end point requires following up participants until
a sufficient number of deaths occur.2,6-8 For example, midostaurin
was recently approved for patients with newly diagnosed FLT3mutated AML based on a clinically significant improvement in OS.9
However, the protocol was amended to perform the primary analysis
with OS as the end point without waiting for the 509 originally
planned OS events to occur, because the original planned OS
events had not yet been reached, likely because of the higherthan-expected rate of hematopoietic cell transplantation (HCT).
This protocol amendment also promoted consideration of eventfree survival (EFS) as the most clinically meaningful secondary
end point for assessment of the effect of midostaurin on the natural
course of FLT3-mutated AML. The molecular, immunophenotypic,
and biologic heterogeneity of AML has allowed the use of targeted
agents tailored to individual patients, but these patient subsets are
small, and trial recruitment is slow as a result of patient selection.10,11
This adds additional time to the clinical trial process. Therefore, there
is an increased interest in surrogate end points that might provide
faster assessments of novel agents to treat AML. EFS is a common
alternative end point in AML. It is similar to progression-free survival,
which has been validated as a surrogate end point in pivotal randomized trials for solid tumors.12-14 In contrast to OS, where
death is the only event of interest, EFS is a composite end point
that includes death resulting from any cause, failure to achieve
complete remission (CR), and relapse from CR as events. Most
failures are from lack-of-remission events or from relapse from
CR and occur within 1 year after treatment initiation.15,16 Therefore,
EFS can be assessed much faster than OS. In addition, EFS is
less affected by HCT or salvage therapy after relapse and takes
into account the entire study population.17-19 These postfailure
interventions are often unspecified in protocols and potentially
bias or dilute the frontline treatment effect, because they can rescue
some patients and prolong the survival of others. Therefore, EFS
may be a more reliable end point than OS for assessment of the
primary treatment effect.
Despite these attractive features, the EFS-based end point is
controversial as a means of accelerating AML approvals. This
results from the potential confounding factor of treatment failure
components of EFS, such as events of induction failure and transplantation, as well as inconsistent definitions of these components.
Therefore, in many protocols, alternative definitions, revisions of
the primary definition, are used for supportive/sensitivity analysis.
The objective of this study was to better understand the different
components of EFS and examine the robustness of efficacy results
using EFS as the primary endpoint, with varying induction failure
definitions and censoring status at the occurence of HCT.

Materials and methods
Trial identification
Since 2003, the Cancer and Leukemia Group B (CALGB; now part
of the Alliance for Clinical Trials in Oncology) has completed five
prospective trials using anthracycline and cytarabine chemotherapy for newly diagnosed patients with AML and reported their
primary end point data. In the current study (A151604), we evaluated
1884 adults with newly diagnosed AML in these five Alliance
(CALGB) trials (Table 1), including 2 randomized phase 3 trials
(CALGB 10201, N 5 506; CALGB 10603, N 5 717) and 3 single-arm
11 JUNE 2019 x VOLUME 3, NUMBER 11

phase 2 trials (CALGB 10503, N 5 546; CALGB 10801, N 5 61;
CALGB 11001, N 5 54).9,20-23 CALGB 10201 enrolled AML
patients age $60 years, and CALGB 11001 enrolled AML patients
age $60 years with FLT3-mutated AML. CALGB 10503 and CALGB
10603 enrolled AML patients age ,60 years, and CALGB 10603
enrolled patients age ,60 years with FLT3-mutated AML. CALGB
10801 enrolled patients age $18 years with the favorable cytogenetic
risk, core binding factor–positive AML. Cytarabine and daunorubicin were used for remission induction, together with other agents in
some studies, and all 5 trials specified a second course of induction
therapy for initial nonresponders.

Statistical analysis
We evaluated 3 definitions of induction failure according to when
CR was assessed: definition 1 (D1), failure to achieve CR by 60 days
after registration/randomization; D2, failure to achieve CR by the
end of all protocol-defined induction courses; and D3, failure to
achieve CR by the end of all protocol-defined treatment. CR was
defined, using the established response criteria for AML therapy,24
as ,5% blasts in cellular marrow with recovery of .1000 neutrophils
per uL (but .1500 neutrophils per uL in CALGB 10201 25 ),
.100 000 platelets per uL, and no red blood cell transfusion
requirement. EFS was defined as the time from randomization/
registration to induction failure using 1 of the 3 definitions, relapse,
or death resulting from any cause. Patients who were last known
to be alive without an EFS event were censored at the date of last
contact. In addition to the 3 definitions of induction failure, we
also considered either censoring or not censoring patients who
underwent HCT at the time of HCT. EFS was separately estimated
in each of the five Alliance (CALGB) trials using the Kaplan-Meier
method,26 with data pooled from across the arms for the randomized
trials. Medians and 95% confidence intervals (CIs) as well as EFS
estimates at predetermined time points were reported. Treatment
effects in the randomized trials were assessed by using the different
EFS definitions to further understand how these definitions affected
trial outcomes.
Each participant signed an institutional review board–approved,
protocol-specific informed consent document in accordance with
federal and institutional guidelines. Data collection and statistical analyses were conducted by the Alliance Statistics and Data
Center. Results analyzed were available in our database as of
13 February 2018.

Results
In total, 1884 adult patients with newly diagnosed AML were
included in this study from 3 single-arm and 2 randomized trials
(Table 1), with a median follow-up of 57 months. Overall, 63%
of patients died and 78% had an event (ie, induction failure within
60 days of treatment initiation, relapse, or death). Among the 5
studies, CALGB 10201 and CALGB 11001 enrolled older patients
(median age, 67 and 69 years, respectively), whereas CALGB
10503 and CALGB 10603 enrolled younger patients (median
age, 47 and 48 years, respectively; Table 2). Approximately half
of the patients were men in all trials except for CALGB 10201
(61% male). Younger AML patients had better performance status.
The percentage of deaths was higher in the AML trials with older
patients (range, 70%-92%) compared with those with younger
patients (range, 50%-56%), with varying length of follow-up
on patients still alive. In addition, the percentage of EFS events
ROBUSTNESS OF EFS IN UNTREATED AML PATIENTS
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Table 1. Trial characteristics
Trial

N

Phase

Period of accrual

Treatment induction*

Population

CALGB 10201

506

3

2003-2006

7 1 3 6 oblimersen

Older AML

CALGB 10503

546

2

2007-2011

71313

Younger AML

CALGB 10603

717

3

2008-2015

7 1 3 6 midostaurin

Younger FLT3-mutated AML

CALGB 10801

61

2

2011-2014

7 1 3 1 dasatinib

CBF AML

CALGB 11001

54

2

2011-2014

7 1 3 1 sorafenib

Older FLT3-mutated AML

CBF, core binding factor.
*7 1 3, anthracycline or cytarabine on days 1-7 and daunorubicin on days 1-3; 7 1 3 1 3, anthracycline or cytarabine on days 1-7, daunorubicin on days 1-3, and etoposide on days 1-3.

was higher in the AML trials with older patients (range, 80%-94%)
compared with younger AML patients (range, 72%-75%). The patients
with favorable cytogenetic risk (core binding factor–positive AML)
enrolled in CALGB 10801 had the lowest death rate (21%) and
EFS event rate (36%).
Depending on when CR status was assessed, the induction failure
rate differed across D1 to D3. Overall patterns were consistent
among the 5 trials (Table 3), where D1 (CR by 60 days from
randomization/registration) yielded the highest induction failure rate,
D3 (CR by end of all protocol-defined treatment) yielded the lowest induction failure rate, and D2 (CR by end of protocol-defined
induction therapy) yielded an intermediate induction failure rate.

Differences among definitions within individual trials ranged between
3% and 8% across the 5 trials. These differences were converted to
EFS estimates.
Median EFS estimates differed considerably according to the
timing for CR used to define induction failure (Table 3). Consistently,
EFS estimates determined with D3 (end-of-treatment definition)
were the highest, EFS estimates determined with D2 (end-of-induction
definition) were intermediate, and EFS estimates determined with
D1 (60-day definition) were the most conservative. This was
expected, because by definition, a longer event-free time would
yield better outcomes. Furthermore, when examining the effect
over time, we observed that the differences in EFS estimates

Table 2. Summary of studies
CALGB 10503 (N 5 546)

CALGB 10603 (N 5 717)

CALGB 10801 (N 5 61)

CALGB 11001 (N 5 54)

CALGB 10201 (N 5 506)

Age, y
Median

48

47

50

67

69

Range

17-60

18-60

19-85

60-82

60-88*

Male

298 (55)

318 (44)

31 (51)

30 (56)

307 (61)

Female

248 (45)

399 (56)

30 (49)

24 (44)

199 (39)

Sex

Performance score
0

187 (34)

306 (43)

28 (46)

23 (43)

151 (30)

1

310 (57)

327 (46)

25 (41)

27 (50)

280 (55)

$2

48 (9)

84 (12)

7 (11)

4 (7)

75 (15)

Deaths

307 (56)

357 (50)

13 (21)

38 (70)

464 (92)

Follow-up, mo†
Median

60

58

34

28

100

51-65

47-67

26-41

18-32

87-105

EFS events

395 (72)

541 (75)

22 (36)

43 (80)

476 (94)

No CR1‡

175 (32)

317 (44)

8 (13)

17 (31)

273 (54)

28 (5)

27 (4)

3 (5)

4 (7)

77 (15)

3 (1)

1 (0)

0 (0)

1 (2)

16 (3)

Induction failure

144 (26)

289 (40)

5 (8)

12 (22)

180 (36)

Relapse after CR1§

181 (33)

182 (25)

13 (21)

20 (37)

164 (32)

39 (7)

42 (6)

1 (2)

6 (11)

39 (8)

IQR

Early death
Early progression

Death without relapse in CR1§

All data are n (%) unless otherwise noted.
IQR, interquartile range.
*One ineligible patient was age 48 y and excluded from the analysis; all other eligible patients were age $60 y in CALGB 10201.
†Defined as lower to upper quantile.
‡No CR1 indicates induction failure by 60 d after registration/randomization.
§CR1 indicates CR during induction (by 60 d after registration/randomization).
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Table 3. EFS estimates determined by using different induction failure definitions with and without censoring at HCT
Induction failure definition

Induction
failure, n (%)

Median
(95% CI) EFS, mo

CALGB 10201 (N 5 506)

Patients
undergoing HCT, %

Patients censored
at time of HCT, %

Median (95% CI) EFS
censoring at time of HCT, mo

9

D1

273 (54)

2.0 (NA)

5

2.0 (NA)

D2

253 (50)

3.0 (2.3-3.8)

4

3.0 (2.3-3.8)

D3

241 (48)

4.3 (3.4-5.4)

5

4.3 (3.3-5.3)

D1

175 (32)

9.8 (8.4-11.7)

16

10.6 (8.9-13.0)

D2

159 (29)

10.6 (9.3-12.4)

16

11.0 (9.5-13.5)

D3

155 (28)

11.2 (9.7-13.8)

17

11.4 (9.8-14.5)

D1

317 (44)

5.5 (2.6-6.7)

21

5.7 (2.6-7.1)

D2

280 (39)

6.9 (5.7-8.3)

21

7.1 (5.7-8.3)

D3

261 (36)

9.7 (8.3-11.7)

27

9.5 (8.2-10.8)

CALGB 10503 (N 5 546)

35

CALGB 10603 (N 5 717)

57

CALGB 10801 (N 5 61)

8

D1

8 (13)

NA (20.9-NA)

3

NA (20.9-NA)

D2

6 (10)

NA (NA)

3

NA (NA)

D3

5 (8)

NA (NA)

3

NA (NA)

CALGB 11001 (N 5 54)

41

D1

17 (31)

6.9 (3.4-11.5)

28

6.0 (3.4-10.2)

D2

15 (28)

8.3 (4.6-11.5)

28

7.8 (4.4-10.2)

D3

15 (28)

8.3 (4.6-11.5)

28

7.8 (4.4-10.2)

NA, not reached.

using the 3 definitions diminished over time (Figure 1). At 1 year
after treatment initiation, the estimated EFS rates ranged from 21%
to 24% in CALGB 10201, 45% to 48% in CALGB 10503, 37% to
46% in CALGB 10603, and 78% to 83% in CALGB 10801; the
estimated EFS rates were 35% for all definitions in CALGB 11001
(Figure 1). For D3 compared with D1, the difference in 1-year EFS
reached as much as 9%.
The effect of HCT on EFS estimation was also investigated. The
percentages of patients who underwent HCT in first CR or after
relapse were 9% in CALGB 10201, 35% in CALGB 10503, 57%
in CALGB 10603, 8% in CALGB 10801, and 41% in CALGB
11001 (Table 3). However, the percentage of patients who were
actually censored at the time of HCT was reduced by approximately
half (range, 3%-28%), thereby indicating that an event of interest
(relapse or death) occurred before transplantation in approximately
half of the patients who underwent HCT. Given that a majority of
patients were not affected by censoring of HCT (ie, their events
happened before HCT), results on EFS were similar regardless
of their HCT status (Table 3; Figure 1).
Additional sensitivity analyses were conducted by using D2 to
calculate EFS, wherein the reported induction end date was replaced
with the date of last clinical assessment during induction. Similarly,
the last follow-up date was replaced with the clinical assessment date, which was defined as the last contact date and used
to calculate EFS. Furthermore, to evaluate the effect of transplantation, only allogeneic HCT was considered instead of all types of
HCT. All of these sensitivity analyses yielded similar results and
consistent conclusions.
11 JUNE 2019 x VOLUME 3, NUMBER 11

For the 2 randomized phase 3 trials (CALGB 10201, CALGB
10603), analysis with the 3 induction failure definitions resulted
in the same overall conclusions about treatment effect. Furthermore, comparisons between the arms in each trial were consistent
across the 3 definitions, and the conclusions about treatment effect
were not affected by the 3 definitions (Table 4). For example, in
CALGB 10603, it was concluded that the addition of multitargeted kinase inhibitor midostaurin to standard chemotherapy
significantly prolonged EFS among patients with AML and an
FLT3 mutation. In our analysis, EFS estimates were significantly
longer in the midostaurin arm than in the placebo arm, with an
HR ranging from 0.71 to 0.79 depending on the induction
failure definition used. In contrast, the addition of oblimersen to
standard chemotherapy failed to improve the outcomes of older
AML patients in CALGB 10201, regardless of induction failure
definition.

Discussion
Appropriate sensitivity analyses for the primary efficacy end point
and the key secondary efficacy end points are often required by
regulatory agencies to evaluate the robustness of efficacy results.27
For example, the potential bias caused by timing and scheduling
of disease progression assessments has received much attention
and is well documented.28 However, specific to AML, no studies so
far have systematically considered the potential confounding
events; for example, non–protocol-mandated HCT and induction failure leading to changes in treatment. In this analysis, we
examined the robustness of EFS in measuring clinical benefit in
untreated AML using individual patient data across studies, and
ROBUSTNESS OF EFS IN UNTREATED AML PATIENTS

From www.bloodadvances.org by guest on July 3, 2019. For personal use only.

1717

Event-free Survival
Induction Fail Def
D1
D1, censor HCT
D2
D2, censor HCT
D3
D3, censor HCT

100
90
80
70
60
50
40
30
20
10
0
0

3

6

9

12

Events/Total
476/506
463/506
476/506
463/506
475/506
459/506

15

Time-Point
12 Months
12 Months
12 Months
12 Months
12 Months
12 Months

18

KM Est (95% CI)
20.6 (17.2-24.3%)
20.1 (16.6-23.8%)
22.2 (18.7-25.9%)
21.5 (17.9-25.3%)
23.8 (20.2-27.6%)
23.1 (19.4-26.9%)
+ Censor

21

D Study 10801
% alive and event–free

% alive and event–free

A Study 10201

100
90
80
70
60
50
40
30
20
10
0

Induction Fail Def
D1
D1, censor HCT
D2
D2, censor HCT
D3
D3, censor HCT

0

24

3

6

100
90
80
70
60
50
40
30
20
10
0
0

3

6

9

12

Events/Total
395/546
353/546
390/546
349/546
385/546
343/546

15

Time-Point
12 Months
12 Months
12 Months
12 Months
12 Months
12 Months

18

KM Est (95% CI)
45.1 (40.9-49.3%)
46.4 (41.8-50.7%)
46.6 (42.4-50.7%)
47.3 (42.7-51.7%)
47.9 (43.6-52.0%)
48.6 (44.0-53.0%)
+ Censor

21

24

Follow–up (months)

% alive and event–free

C Study 10603

Induction Fail Def
D1
D1, censor HCT
D2
D2, censor HCT
D3
D3, censor HCT

100
90
80
70
60
50
40
30
20
10
0
0

3

6

9

12

Events/Total
541/717
474/717
524/717
459/717
499/717
416/717

15

E Study 11001
% alive and event–free

% alive and event–free

Induction Fail Def
D1
D1, censor HCT
D2
D2, censor HCT
D3
D3, censor HCT

9

Time-Point
12 Months
12 Months
12 Months
12 Months
12 Months
12 Months

12

KM Est (95% CI)
78.0 (65.1-86.6%)
77.7 (64.6-86.4%)
81.4 (68.9-89.2%)
81.0 (68.3-89.0%)
83.0 (70.7-90.5%)
82.7 (70.1-90.3%)
+ Censor

15

18

21

24

Follow–up (months)

Follow–up (months)

B Study 10503

Events/Total
22/61
21/61
20/61
19/61
19/61
18/61

Induction Fail Def
D1
D1, censor HCT
D2
D2, censor HCT
D3
D3, censor HCT

100
90
80
70
60
50
40
30
20
10
0
0

3

6

9

12

Events/Total
43/54
37/54
43/54
37/54
43/54
37/54

Time-Point
12 Months
12 Months
12 Months
12 Months
12 Months
12 Months

15

18

KM Est (95% CI)
35.2 (22.8-47.8%)
24.7 (11.7-40.3%)
35.2 (22.8-47.8%)
23.7 (11.0-39.0%)
35.2 (22.8-47.8%)
23.7 (11.0-39.0%)
+ Censor

21

24

Follow–up (months)
Time-Point
12 Months
12 Months
12 Months
12 Months
12 Months
12 Months

18

KM Est (95% CI)
37.1 (33.6-40.7%)
36.6 (32.6-40.5%)
39.5 (35.9-43.1%)
38.3 (34.3-42.3%)
45.6 (41.9-49.2%)
43.8 (39.5-48.0%)
+ Censor

21

24

Follow–up (months)
Figure 1. Kaplan-Meier (KM) curves of EFS by induction failure definition (fail def) D1 to D3, with and without censoring at HCT. KM curves of EFS in CALGB
10201 (A), CALGB 10503 (B), CALGB 10603 (C), CALGB 10801 (D), and CALGB 11001 (E). Green curves represent EFS estimates (est) by D1 (no CR by 60 days after
registration/randomization), blue curves represent EFS estimates by D2 (no CR by the end of all protocol-defined induction courses), and red curves represent EFS estimates
by D3 (no CR by the end of all protocol-defined treatment). Solid curves represent EFS analysis with censoring at non–protocol-specified HCT, and dashed curves represent
EFS analysis without censoring at HCT.

we provide recommendations on trial design using EFS as an
end point.
Although relapse and death are firm end points, the determination
of induction failure is not consistent across studies. Median EFS
estimates differed considerably depending on the timing used to
define induction failure, and the magnitude of the difference ranged
from 14% to 115%. In all 5 studies of untreated AML patients who
received standard intensive induction chemotherapies, EFS estimates determined by D3 (failure to achieve CR during the entire
protocol treatment) were consistently the highest because of the
length of EFS. EFS estimates determined by D1 (failure to achieve
CR by 60 days) were the most conservative, and EFS estimates
determined by D2 (failure to achieve CR after all induction therapies)
were intermediate. This suggests that incorrect conclusions about
1718
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efficacy could be made in a single-arm trial if the definition of EFS
used in the trial were inconsistent with the definition used to determine the historical control estimate. However, in randomized trials,
HRs have been shown to be insusceptible to such bias. Therefore,
more emphasis should be placed on using HRs to measure clinical
benefit instead of the Kaplan-Meier estimates of EFS medians in
trials with a concurrent control.
To further explore the reason behind the discrepancy between
EFS using D1 vs D2, we specifically studied patients who were
considered to have induction failure by D1 but not by D2. For
example, in CALGB 10603, 62 patients achieved a CR after
60 days postrandomization, but before their reported end date
of all induction courses. Of these 62 patients, only 1 achieved a CR
during the first induction; the other 61 patients achieved a CR
11 JUNE 2019 x VOLUME 3, NUMBER 11
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Table 4. EFS estimates determined by using different induction
failure definitions for randomized trials CALGB 10201 and
CALGB 10603

Induction failure
definition

Median (95% CI) EFS by
arm, mo

Comparison of EFS
between arms
P

Arm 1

Arm 2

HR (95% CI)

D1

2 (2.0-3.4)

2.0 (NA-NA)

1.03 (0.86-1.23)

D2

3.3 (2.4-5.3)

2.7 (1.9-4.3)

1.02 (0.85-1.22)

.850

D3

4.5 (3.4-5.7)

3.8 (2.3-5.7)

1.04 (0.87-1.25)

.670

CALGB 10201
.770

CALGB 10603
D1

7.8 (4.7-10.6)

2.8 (2.0-5.9)

0.79 (0.67-0.94)

.005

D2

9.5 (7.3-13.1)

5.5 (3.0-6.7)

0.76 (0.64-0.90)

.002

D3

14.5 (10.6-17.3) 7.2 (6.0-8.9)

0.71 (0.60-0.85) ,.001

HR, hazard ratio; NA, not reached.

during their second induction therapy. Because of the timing of
their CRs, using D1, these patients were considered to have
induction failures with their EFS time equal to 60 days (1.97 months),
whereas using D2, they were considered to be in induction remission until relapse or death, with a median EFS of 23.8 months
(95% CI, 11.8 to not reached). These data are included in supplemental Table 3. Similarly, when comparing D2 vs D3, we identified
25 patients from CALGB 10603 who achieved a CR postinduction;
half of the patients in this group achieved a CR 42 days postinduction
(25% to 75% quantile, 23-85 days), suggesting that they were
receiving protocol consolidation therapy when they achieved a CR.
Although we evaluated the effect of the timing of remission assessment, a limitation of the study is that we did not evaluate the effect of
what constitutes a remission in the definition of EFS. For example,
less stringent response criteria include CR without platelet recovery
and CR with incomplete hematologic recovery. Another limitation
of our study is that we did not take into account adherence to the
protocol induction therapy. For example, in another AML trial (H049),6,29
.90% of patients who did not have a CR after the first course of
induction received a second course as required by the protocol,
whereas in trial S0106,30 the adherence rate was only ;55%. This
may relate to differences in clinical practice; in the United States,
physicians may remove a patient from protocol therapy on day 14 if
bone marrow biopsy results indicate a high burden of disease, but in
Europe, 2 cycles of induction are customarily administered regardless of poor early response. However, because induction failure is
delayed when a second course of induction is received by initial
nonresponders, the EFS becomes longer just by improving protocol
adherence. In addition, subsequent treatment information, including
HCT, was not systematically recorded in the clinical trials considered
in this analysis, and this is another limitation. Statistical approaches,
such as competing risk analysis and multistate models, are more
appropriate for investigation of the effect of off-protocol transplantation on these outcomes.
Defining the clinical benefit of therapy in AML is complicated by
disease- and treatment-specific considerations. Although CR has
been uniformly defined in AML and is a more tractable end point,
several recent studies have indicated a dissociation between CR
and OS (ie, improvement in CR but no improvement in OS compared
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with controls) under some conditions.31,32 Minimal (or measureable)
residual disease has been used as an alternative end point to support
the regulatory approval of agents for both chronic myeloid leukemia
and acute lymphoblastic leukemia. The use of minimal residual
disease in AML has been hampered by the lack of standardized
assessments. However, EFS has the advantage of reaching an end
point sooner than OS, but unlike OS, EFS is not influenced by
subsequent treatments administered after failure to achieve or
maintain a remission and thus provides a more precise assessment
of the efficacy of a particular drug.
The analysis presented here is different from a surrogacy analysis of
EFS to OS, where 2 levels of correlations (ie, individual patient-level
correlation and trial-level correlation) need to be formally established
using a meta-analytical approach.33 Ongoing work is focused on
collecting data from trials conducted across the National Cancer
Institute National Clinical Trials Network to perform a formal surrogacy
analysis of EFS to OS.
To conclude, this is by far the largest study (N 5 1884) to evaluate
the robustness of EFS and consider potentially confounding events
using individual patient data collected from 5 CALGB trials. Although
analysis of the randomized trials revealed that the trial conclusions
remained unaffected, median EFS estimates differed considerably
based on the timing of CR used in defining induction failure. The
magnitude of difference in these estimates could be large enough
in most cases to lead to incorrect conclusions about efficacy in
a single-arm trial, if the trial definition were not consistent with the
definition used for the historical control. Therefore, the timing of
CR should be carefully examined in the historical control data used
to guide the design of single-arm trials using EFS as the primary
end point.
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Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from
an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.

4.
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Löwenberg B, Ossenkoppele GJ, van Putten W, et al; Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin
in older patients with acute myeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155]. N Engl J Med. 2009;361(13):
1235-1248.

7.

Nand S, Othus M, Godwin JE, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Blood. 2013;122(20):3432-3439.

8.

Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research
council AML15 trial. J Clin Oncol. 2013;31(27):3360-3368.

9.

Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;
377(5):454-464.

10. Gao W, Estey E. Moving toward targeted therapies in acute myeloid leukemia. Clin Adv Hematol Oncol. 2015;13(11):748-754.
11. Burnett AK, Knapper S. Targeting treatment in AML. Hematology Am Soc Hematol Educ Program. 2007;2007:429-434.
12. Herndon TM, Demko SG, Jiang X, et al. U.S. Food and Drug Administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with
melanoma. Oncologist. 2012;17(10):1323-1328.
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